Stealth BioTherapeutics Return on Equity

Stealth BioTherapeutics (MITO) currently reports a ROE of 103.77%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Stealth BioTherapeutics's ROE history and peer comparisons.

Stealth BioTherapeutics's ROE of 103.77% is higher than the Healthcare sector average of 11.15%. That is roughly 830.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Stealth BioTherapeutics's current 103.77% should be judged against Healthcare norms (sector average: 11.15%) and against MITO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 103.77%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Stealth BioTherapeutics, and consider following MITO for alerts when major investors trade the stock.

Stealth BioTherapeutics is classified in the Healthcare sector. On ROE, it currently shows 103.77% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MITO with unrelated industries.